Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Pfizer Inc.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
Weak signals across every dimension
Get notified when we ship meaningful updates. No spam, no daily noise.
1 of 5 met · composite in line with peers
Business quality, valuation against the sector, and position in the 52-week range — whether they line up or not.
Mixed signals
Profitability
3/4
Debt & liquidity
0/3
Efficiency
2/2
Pfizer's cash generation stands out: FCF yield runs 6.8%, well above the sector median 3.8%, and the company has beaten consensus earnings in recent quarters. Yet the balance sheet tells a different story. Debt/EBITDA sits at 5.3×, +72% above the sector median 3.1×, leaving less room for downturns or investment. Revenue growth of -1.6% trails the sector median 5.9% by -128%, a gap that has persisted. The F-Score of 5/9 reflects mixed signals: profitability holds, but long-term debt is rising and the company faces structural headwinds. Valuation offers some cushion—the P/B of 1.9× sits -73% below the median—yet that discount mirrors the underlying weakness rather than a hidden bargain. Consensus expects earnings growth in line with the realized three-year record, so near-term surprises appear limited.
| Ticker | Name | F-Score | ROE | Revenue YoY | Op. margin |
|---|---|---|---|---|---|
| ABBV | AbbVie | 8/9 | 15 367% |
Quarter-by-quarter classification · a retrospective read by the current logic · not a price forecast
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice. The method did not see these quarters in real time; this is the current logic applied to past reports.
The market prices in earnings growth.
Price against next year's expected earnings. The forward P/E already carries analyst optimism — read it alongside the “Versus consensus” line.
A forward P/E below the current one means the market expects earnings to grow; above it, to fall. The historical growth is realized figures from SEC filings, not a forecast.
A description of what the market and analysts expect. Not a price forecast and not investment advice. Analyst forecasts run systematically optimistic over long horizons — read them with that discount.
When Pfizer reports on 2026-11-02, track revenue year over year against the current -5.86% figure and check whether FCF yield holds near 3.78%. A sustained improvement in revenue growth would be the clearest sign the mixed F-Score is shifting.
On SEC EDGAR, open Pfizer's most recent 10-K and focus on the Liquidity section — Debt/EBITDA sits 72% above the sector median at 3.06×, and management's discussion should explain the repayment timeline. Also check the pipeline disclosures that underpin the EV/EBITDA of 23.4×.
Pick two or three names from the Health Care table in section 06 and line up one metric — Debt/EBITDA or FCF yield works well given Pfizer's mixed signals. The table is alphabetical with no ranking, so the selection and the comparison are yours to make.
Steps you can check yourself, based on the figures in this brief.
Piotroski F-Score: nine binary tests of financial strength from the annual report. A ✓ marks a test passed, a dot (·) a test failed.
Over 4 years: -13%-82%+105%-8%
Over 4 years: 1.127.074.505.27
Over 4 years: +24%-41%+7%-2%
The context on the right shows how each figure compares with the sector median. The trend below tracks the change over recent fiscal years.
Beat consensus in 8 of 8 recent quarters — the company clears estimates regularly (consensus is often set conservatively).
Last quarter's EPS against consensus, plus the estimated date of the next report.
| +9% |
| 25% |
| ABT | Abbott | 6/9 | 13% | +6% | 18% |
| AMGN | Amgen | 7/9 | 106% | +10% | 25% |
| BMY | Bristol-Myers Squibb | 8/9 | 41% | -0% | — |
| CVS | CVS Health | 6/9 | 2% | +8% | 1% |
| DHR | Danaher | 5/9 | 7% | +3% | 19% |
| GILD | Gilead Sciences | 8/9 | 40% | +2% | 34% |
| ISRG | Intuitive Surgical | 6/9 | 17% | +21% | 29% |
| JNJ | Johnson & Johnson | 4/9 | 35% | +6% | — |
| LLY | Eli Lilly | 7/9 | 101% | +45% | — |
| MRK | Merck | 4/9 | 37% | +1% | — |
| PFE | Pfizer Inc. | 5/9 | 9% | -2% | — |
| TMO | Thermo Fisher | 5/9 | 13% | +4% | 17% |
| UNH | UnitedHealth | 7/9 | 18% | +12% | 4% |
A sample of 14 companies in the sector including the target, alphabetical, unranked. Data from the latest SEC annual reports.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
A simplified retrospective read: no analyst forecast (not available historically); the source is the annual report as of the date, so neighbouring quarters can rest on the same data. Quarters with the same classification in a row are merged into one row — each row is one change in the read, not a separate quarter. One ticker is an illustration of the classification logic, not statistics. How we calculate →